30 Sept. 2023. The Nasdaq Biotechnology Index, an indicator of investor sentiment in an industry based on science, continued heading down during the third quarter of 2023. NBI closed yesterday at 3,954, a decline of 5.3 percent since the start of trading on 3 Jan. 2023, and down 2.5 percent since the beginning of July.
The index, compiled with share prices of 262 biotechnology and pharmaceutical companies listed on the Nasdaq exchange, began rising during most of July, closing at 4,175 on 21 July, about the same as its price on the first day of trading this year. Then NBI fluctuated between 4,000 and 4,150 through the rest of July and August, only to decline through September to yesterday’s closing price below 4,000. The index’s price fluctuations showed a similar pattern in the second quarter of this year.
Despite the downward trend this year, NBI is still ahead by 4.9 percent of its close at the end of Sept. 2022. By comparison, however, the Nasdaq Composite Index, an indicator of investment sentiment in the technology sector overall, is up by 21.4 percent since the beginning of 2023 and 20 percent over the past 12 months.
More from Science & Enterprise:
- Infographic – Biotech Index Shows Life, Ends Flat This Year
- Infographic – Biotech Index Down in Q1 2023
- Infographic – Biotech Index Struggles to Regain Ground
We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the entire page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.
[wpedon id=”42724″ align=”center”]
* * *
You must be logged in to post a comment.